EPISODE · Mar 4, 2026 · 28 MIN
GLP-1 Weight Loss Medications: The Good, the Bad and the Ugly
from Energize and Revitalize with Dr. Amy · host Dr. Amy Coopersmith
GLP-1 medications like Ozempic, Wegovy, and Mounjaro are everywhere—but are they the right tool for sustainable health and weight loss? In this solo episode, I break down the good, the bad, and the ugly of GLP-1 medications, including what most people are not being told about muscle loss, metabolism, and long-term maintenance. We discuss: How GLP-1 medications actually work The benefits beyond weight loss (blood sugar, inflammation, cardiometabolic health) The risks and side effects—including muscle loss, fatigue, hair loss, and nutrient deficiencies Why protein intake is critical (and how much you really need) The role of resistance training in protecting muscle and metabolism Why losing weight without preserving muscle can backfire Strategies to minimize muscle loss while using GLP-1s Who may benefit from these medications—and who should pause before starting This is a non-judgmental, science-based conversation about using GLP-1 medications thoughtfully, ethically, and safely—without shame or stigma. If you're considering GLP-1 therapy, currently using it, or supporting patients or loved ones on these medications, this episode will give you the context you need to make informed decisions. Learn more about Dr. Amy and Amethyst Wellness: https://www.amethystwellness.com Subscribe to our newsletter: Contact | Amethyst Wellness Connect with us: [email protected] Also available on YouTube: https://youtu.be/pJ3NQTmpwXw #GLP1 #GLP1Medications #WeightLossMedications #Ozempic #Wegovy #Mounjaro #MuscleHealth #ProtectYourMuscle #ProteinIntake #StrengthTraining #MetabolicHealth #HormoneHealth #HealthyWeightLoss #FunctionalMedicine #WholeBodyHealth #EnergizePodcast #AmethystWellness #DrAmy
NOW PLAYING
GLP-1 Weight Loss Medications: The Good, the Bad and the Ugly
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m